← Back to Screener
Harrow, Inc. Common Stock (HROW)
Price$40.50
Favorite Metrics
Price vs S&P 500 (26W)-2.43%
Price vs S&P 500 (4W)10.98%
Market Capitalization$1.51B
All Metrics
P/CF (Annual)34.37x
Book Value / Share (Quarterly)$1.41
P/TBV (Annual)224.79x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)45.39%
Cash Flow / Share (Quarterly)$1.15
Price vs S&P 500 (YTD)-21.28%
Gross Margin (TTM)75.05%
Net Profit Margin (TTM)-1.89%
EPS (TTM)$-0.16
10-Day Avg Trading Volume0.48M
EPS Excl Extra (TTM)$-0.16
Revenue Growth (5Y)40.99%
EPS (Annual)$-0.14
ROI (Annual)-1.74%
Gross Margin (Annual)75.05%
Net Profit Margin (5Y Avg)-14.03%
Cash / Share (Quarterly)$1.96
Revenue Growth QoQ (YoY)33.31%
ROA (Last FY)-1.29%
Revenue Growth TTM (YoY)36.41%
EBITD / Share (TTM)$0.66
ROE (5Y Avg)-55.97%
Operating Margin (TTM)8.36%
Cash Flow / Share (Annual)$1.15
P/B Ratio28.75x
P/B Ratio (Quarterly)34.60x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)6.16x
Net Interest Coverage (TTM)0.94x
ROA (TTM)-1.40%
EPS Growth QoQ (YoY)-5.63%
EV / EBITDA (TTM)67.86x
EPS Incl Extra (Annual)$-0.14
Current Ratio (Annual)2.20x
Quick Ratio (Quarterly)1.93x
3-Month Avg Trading Volume0.67M
52-Week Price Return68.82%
EV / Free Cash Flow (Annual)39.24x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.06
P/S Ratio (Annual)5.54x
Asset Turnover (Annual)0.68x
52-Week High$54.85
Operating Margin (5Y Avg)3.04%
EPS Excl Extra (Annual)$-0.14
CapEx CAGR (5Y)5.08%
Tangible BV CAGR (5Y)-24.83%
26-Week Price Return4.46%
Quick Ratio (Annual)1.93x
13-Week Price Return-16.48%
Total Debt / Equity (Annual)4.64x
Current Ratio (Quarterly)2.20x
Enterprise Value$1,678.06
Revenue / Share Growth (5Y)31.46%
Asset Turnover (TTM)0.74x
Book Value / Share Growth (5Y)5.88%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)5.61x
Pretax Margin (Annual)-0.50%
Cash / Share (Annual)$1.96
3-Month Return Std Dev72.55%
Gross Margin (5Y Avg)73.23%
Net Income / Employee (TTM)$-0
EBITDA CAGR (5Y)62.38%
EBITDA Interim CAGR (5Y)39.57%
ROE (Last FY)-9.80%
Net Interest Coverage (Annual)0.94x
EPS Basic Excl Extra (Annual)$-0.14
P/FCF (TTM)34.48x
Receivables Turnover (TTM)2.40x
EV / Free Cash Flow (TTM)39.24x
Total Debt / Equity (Quarterly)4.64x
EPS Incl Extra (TTM)$-0.16
Receivables Turnover (Annual)2.40x
ROI (TTM)-1.81%
P/S Ratio (TTM)5.54x
Pretax Margin (5Y Avg)-13.57%
Revenue / Share (Annual)$7.41
Tangible BV / Share (Annual)$0.06
Forward P/E85.94x
Price vs S&P 500 (52W)34.19%
Year-to-Date Return-17.35%
5-Day Price Return6.86%
EPS Normalized (Annual)$-0.14
ROA (5Y Avg)-8.17%
Net Profit Margin (Annual)-1.89%
Month-to-Date Return14.86%
Cash Flow / Share (TTM)$-0.15
EBITD / Share (Annual)$0.67
Operating Margin (Annual)8.36%
LT Debt / Equity (Annual)4.64x
P/CF (TTM)34.37x
ROI (5Y Avg)-9.96%
LT Debt / Equity (Quarterly)4.64x
EPS Basic Excl Extra (TTM)$-0.16
P/TBV (Quarterly)224.79x
P/B Ratio (Annual)34.60x
Inventory Turnover (TTM)5.54x
Pretax Margin (TTM)-0.50%
Book Value / Share (Annual)$1.41
Price vs S&P 500 (13W)-18.86%
Beta0.32x
P/FCF (Annual)35.26x
Revenue / Share (TTM)$7.30
ROE (TTM)-10.00%
52-Week Low$21.12
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.29
4.29
4.29
4.29
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
HROWHarrow, Inc. Common Stock | 5.54x | 36.41% | 75.05% | — | $40.50 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Harrow Inc is a specialty pharmaceutical company that develops and commercializes ophthalmic medications for the U.S. market, including branded products like Iheezo, Vevye, and Maxitrol. The company generates revenue through its Branded segment and ImprimisRx platform, while advancing a clinical pipeline targeting conditions such as dry eye disease, glaucoma, and cataracts across both front and back-of-the-eye indications.